JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

Home・Elenco Azioni・MacroGenics Inc

Search

MacroGenics Inc

Aperta

SettoreSettore sanitario

3.13 -2.8

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.13

Massimo

3.26

Metriche Chiave
By Trading Economics
Entrata	-31M -14M
Vendite	-32M 41M
EPS	-0.22
Margine di Profitto	-34.333
Dipendenti	293
EBITDA	-37M -15M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+102.24% upside

Dividendi
By Dow Jones
Utili prossimi	12 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	71M 194M
Apertura precedente	5.93
Chiusura precedente	3.13

Notizie sul Sentiment di mercato

By Acuity

31%

69%

106 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

1.47 / 1.64 Supporto e resistenza

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 mag 2026, 22:17 UTC

Utili

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mag 2026, 23:47 UTC

Utili

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mag 2026, 23:45 UTC

Utili

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mag 2026, 23:45 UTC

Utili

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mag 2026, 23:40 UTC

Discorsi di Mercato

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mag 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mag 2026, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mag 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mag 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mag 2026, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mag 2026, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

4 mag 2026, 22:39 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mag 2026, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

4 mag 2026, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mag 2026, 22:37 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mag 2026, 22:26 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mag 2026, 22:02 UTC

Utili

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mag 2026, 22:00 UTC

Discorsi di Mercato

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mag 2026, 21:52 UTC

Utili

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mag 2026, 21:50 UTC

Utili

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mag 2026, 21:50 UTC

Utili

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mag 2026, 21:49 UTC

Utili

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mag 2026, 21:44 UTC

Utili

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mag 2026, 21:44 UTC

Utili

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mag 2026, 21:43 UTC

Utili

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mag 2026, 21:41 UTC

Utili

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mag 2026, 21:40 UTC

Utili

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

102.24% in crescita

Previsioni per 12 mesi

Media 6.33 USD 102.24%

Alto 9 USD

Basso 4 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

2

Acquista

2

Mantieni

0

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a MacroGenics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.47 / 1.64Supporto e resistenza

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

106 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Altri titoli del settore

JNJ

Johnson and Johnson

225.83

UNH

UnitedHealth Group Inc

362.86

TMO

Thermo Fisher Scientific Inc

464.87

ISRG

Intuitive Surgical Inc

449.45

ABT

Abbott Laboratories

87.44

Live chat